| dbo:abstract |
Belinostat (trade name Beleodaq, previously known as PXD101) is a histone deacetylase inhibitor drug developed by TopoTarget for the treatment of hematological malignancies and solid tumors. It was approved in July 2014 by the US FDA to treat peripheral T-cell lymphoma. In 2007 preliminary results were released from the Phase II clinical trial of intravenous belinostat in combination with carboplatin and paclitaxel for relapsed ovarian cancer. Final results in late 2009 of a phase II trial for T-cell lymphoma were encouraging.Belinostat has been granted orphan drug and fast track designation by the FDA, and was approved in the US for the use against peripheral T-cell lymphoma on 3 July 2014. It is not approved in Europe as of August 2014. The approved pharmaceutical formulation is given intravenously. Belinostat is primarily metabolized by UGT1A1; the initial dose should be reduced if the recipient is known to be homozygous for the UGT1A1*28 allele. (en) Белиностат (Belinostat) — лекарственный препарат, предназначенный для лечения периферической Т-клеточной лимфомы. Разработан компанией . Получил статус орфанного препарата и одобрен FDA в 2014 г. (ru) |
| dbo:alternativeName |
Beleodaq (en) |
| dbo:bioavailability |
100.000000 (xsd:float) |
| dbo:casNumber |
866323-14-0 |
| dbo:chEBI |
61076 |
| dbo:chEMBL |
408513 |
| dbo:fdaUniiCode |
F4H96P17NZ |
| dbo:kegg |
D08870 |
| dbo:pubchem |
6918638 |
| dbo:thumbnail |
wiki-commons:Special:FilePath/Belinostat.svg?width=300 |
| dbo:wikiPageID |
22939577 (xsd:integer) |
| dbo:wikiPageLength |
5758 (xsd:nonNegativeInteger) |
| dbo:wikiPageRevisionID |
1121585748 (xsd:integer) |
| dbo:wikiPageWikiLink |
dbr:Carboplatin dbr:FDA_Fast_Track_Development_Program dbr:Allele dbr:Homozygous dbr:US_FDA dbr:Orphan_drug dbr:T-cell_lymphoma dbr:Peripheral_T-cell_lymphoma dbr:TopoTarget dbc:Histone_deacetylase_inhibitors dbr:Paclitaxel dbr:Histone_deacetylase_inhibitor dbr:Pharmaceutical_formulation dbc:Sulfonamides dbc:Hydroxamic_acids dbc:Acrylamides dbr:UGT1A1 dbr:Intravenous dbr:UDP_glucuronosyltransferase_1_family,_polypeptide_A1 dbr:Ovarian_cancer |
| dbp:atcPrefix |
L01 (en) |
| dbp:atcSuffix |
XH04 (en) |
| dbp:bioavailability |
100.0 |
| dbp:c |
15 (xsd:integer) |
| dbp:casNumber |
866323 (xsd:integer) |
| dbp:chebi |
61076 (xsd:integer) |
| dbp:chembl |
408513 (xsd:integer) |
| dbp:chemspiderid |
5293831 (xsd:integer) |
| dbp:excretion |
Urine (en) |
| dbp:h |
14 (xsd:integer) |
| dbp:iupacName |
-N-Hydroxy-3-[3-phenyl]prop-2-enamide (en) |
| dbp:kegg |
D08870 (en) |
| dbp:legalUs |
Rx-only (en) |
| dbp:metabolism |
dbr:UDP_glucuronosyltransferase_1_family,_polypeptide_A1 |
| dbp:n |
2 (xsd:integer) |
| dbp:o |
4 (xsd:integer) |
| dbp:pregnancyUs |
D (en) |
| dbp:proteinBound |
92.900000 (xsd:double) |
| dbp:pubchem |
6918638 (xsd:integer) |
| dbp:routesOfAdministration |
dbr:Intravenous |
| dbp:s |
1 (xsd:integer) |
| dbp:smiles |
O=Sc2ccccc2 (en) |
| dbp:stdinchi |
1 (xsd:integer) |
| dbp:stdinchikey |
NCNRHFGMJRPRSK-MDZDMXLPSA-N (en) |
| dbp:synonyms |
PXD101 (en) |
| dbp:tradename |
Beleodaq (en) |
| dbp:unii |
F4H96P17NZ (en) |
| dbp:wikiPageUsesTemplate |
dbt:Antineoplastic-drug-stub dbt:As_of dbt:Infobox_drug dbt:Reflist dbt:Rp dbt:Short_description dbt:Cascite dbt:Chemspidercite dbt:Ebicite dbt:Fdacite dbt:Stdinchicite dbt:Drugs.com dbt:Intracellular_chemotherapeutic_agents dbt:HDAC_inhibitors |
| dcterms:subject |
dbc:Histone_deacetylase_inhibitors dbc:Sulfonamides dbc:Hydroxamic_acids dbc:Acrylamides |
| gold:hypernym |
dbr:Drug |
| rdf:type |
owl:Thing dul:ChemicalObject dbo:ChemicalSubstance wikidata:Q8386 yago:WikicatSulfonamides yago:Agent114778436 yago:Antibacterial102716205 yago:Antineoplastic102722458 yago:CausalAgent100007347 yago:CytotoxicDrug103157987 yago:Drug103247620 yago:Inhibitor114724436 yago:Matter100020827 yago:Medicine103740161 yago:PhysicalEntity100001930 yago:WikicatHistoneDeacetylaseInhibitors dbo:Drug yago:Substance100020090 yago:SulfaDrug104352070 yago:WikicatExperimentalCancerDrugs |
| rdfs:comment |
Белиностат (Belinostat) — лекарственный препарат, предназначенный для лечения периферической Т-клеточной лимфомы. Разработан компанией . Получил статус орфанного препарата и одобрен FDA в 2014 г. (ru) Belinostat (trade name Beleodaq, previously known as PXD101) is a histone deacetylase inhibitor drug developed by TopoTarget for the treatment of hematological malignancies and solid tumors. It was approved in July 2014 by the US FDA to treat peripheral T-cell lymphoma. The approved pharmaceutical formulation is given intravenously. Belinostat is primarily metabolized by UGT1A1; the initial dose should be reduced if the recipient is known to be homozygous for the UGT1A1*28 allele. (en) |
| rdfs:label |
Belinostat (en) Белиностат (ru) |
| owl:sameAs |
freebase:Belinostat yago-res:Belinostat wikidata:Belinostat http://or.dbpedia.org/resource/ବେଲିନୋଷ୍ଟାଟ dbpedia-ru:Belinostat dbpedia-sh:Belinostat dbpedia-sr:Belinostat dbpedia-vi:Belinostat https://global.dbpedia.org/id/4WjdY |
| prov:wasDerivedFrom |
wikipedia-en:Belinostat?oldid=1121585748&ns=0 |
| foaf:depiction |
wiki-commons:Special:FilePath/Belinostat.svg |
| foaf:isPrimaryTopicOf |
wikipedia-en:Belinostat |
| is dbo:wikiPageRedirects of |
dbr:Beleodaq dbr:C15H14N2O4S dbr:PXD101 |
| is dbo:wikiPageWikiLink of |
dbr:Beleodaq dbr:Vorinostat dbr:Epstein–Barr_virus–associated_lymphoproliferative_diseases dbr:Lung_cancer dbr:C15H14N2O4S dbr:Chromatin_remodeling dbr:Histone_deacetylase_inhibitor dbr:Ivars_Kalviņš dbr:Hydroxamic_acid dbr:ATC_code_L01 dbr:Spectrum_Pharmaceuticals dbr:List_of_drugs:_Be dbr:PXD101 |
| is foaf:primaryTopic of |
wikipedia-en:Belinostat |
